

PO001 Preclinical activity of glypican-3 (GPC3) and NKp46 directed FLEX-NK™ engager antibody (CYT-303) in combination with iPSC derived natural killer cells (iNKs) or peripheral blood (PB) NK cells in hepatocellular carcinoma (HCC). Antonio R. Arulanandam. Cytovia Therapeutics, Natick, MA, United States.

PO002, PR03 Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing. Sarah Cappuyns. University Hospitals Leuven, Leuven, Belgium.

PO003 Combination therapy with Nivolumab/Bevacizumab is safe and effective in patients with recurrent hepatocellular carcinoma after liver transplant. Lorenza Di Marco. Clinical and Experimental Medicine PhD Program, Unimore, Modena, Italy.

PO004, PR04 CRISPR lipid nanoparticle modulates the tumor immune microenvironment of liver metastases by genetically eliminating M2 polarization pathway in macrophages. Tyler Galbraith. Houston Methodist Research Institute, Houston, TX, United States.

PO005 Obesity-associated Visfatin, and Silibinin in an In Vitro and In Vivo Model of Liver Cancer. Elisa Pedone. Texas State University, San Marcos, TX, United States.

PO006 The Role of Obesity-associated Allograft Inflammatory Factor-1 in Liver Cancer Cell Growth. Jessie Waltenbaugh. Texas State University, San Marcos, TX, United States.


PO007, PR06 Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing. Amanda J. Craig. Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

PO008 Aggressive hepatocellular carcinoma and intrahepatic cholangiocarcinoma cell lines share similar response to proangiogenic priming. Adriana Romanzi. Clinical & Experimental Medicine PhD Program, Unimore, Modena, Italy.

PO009 Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma. Jordi Abril-Fornaguera. Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PO010 Molecular characterization of pediatric hepatocellular carcinoma: genomic, methylomic and transcriptomic analysis. Juan Carrillo-Reixach. IGTP, Badalona, Spain.

PO011 Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers. Álvaro Del Río-Álvarez. Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain.



PO012 In silico drug repurposing identifies mebendazole as a treatment option for chemoresistant hepatoblastoma. Roland Kappler. Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

PO013 Patient-derived xenograft mouse models of hepatoblastoma for a personalized medicine pipeline. Sarah E. Woodfield. Baylor College of Medicine, Houston, TX, United States.

PO014 Genome-wide mapping of oncogenic pathways and genetic modifiers of chemotherapy using a high-risk hepatoblastoma genetic model. Jun Yang. St Jude Children's Research Hospital, Memphis, TN, United States.

PO015 Intrinsic and extrinsic role of Axl in models of hepatocellular carcinoma. Kristina Breitenecker. Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

PO016 Spatial transcriptomic profiling to characterize the tumor-vascular interactome of hepatocellular carcinoma. Joseph W. Franses. Massachusetts General Hospital Division of Hematology-Oncology, Boston, MA, United States.

PO017 HBV alters YAP regulation in liver cancer by remodeling PP2A complexes. John Gordan. UC San Francisco, San Francisco, CA, United States.

PO018 The development of chemoresistant liver cancer cells to explore visfatin and the IGF-1/IR/Akt axis. Curissa Groll. Texas State University, Kyle, TX, United States.

PO019 Gas6/Axl signaling induces PRAME expression in hepatocellular carcinoma. Viola Hedrich. Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.


PO020 Identification of lipid species: potential biomarkers for early detection of hepatocellular carcinoma. Kit Yee Leung. University of Nevada, Las Vegas, Las Vegas, NV, United States.

PO021, PR01 Computational identification of targetable dependencies in hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) replication. Huat Chye Lim. University of California, San Francisco, San Francisco, CA, United States.

PO022, PR02 PMEPA1 has an oncogenic role in the context of TGF- β signaling in hepatocellular carcinoma. Marta Piqué-Gili. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PO023 Uncovering hepatitis B virus-induced signaling changes in hepatocellular carcinoma. Rigney E. Turnham. UCSF, San Francisco, CA, United States.

PO024 Combination therapy with PXS-5505 improves chemotherapeutic efficacy and reduces myeloid immune suppression in murine cholangiocarcinoma – a novel therapeutic strategy for clinical translation. Paul R. Burchard. University of Rochester Medical Center, Rochester, NY, United States.



An AACR Special Conference on
**Advances in the Pathogenesis
and Molecular Therapies
of Liver Cancer**
May 5-8, 2022 | Boston, MA

AACR
American Association
for Cancer Research®
711049D

PO025 GM-CSF neutralization enhances the efficacy of chemotherapy in an orthotopic murine model of cholangiocarcinoma. Yatee A. Dave. University of Rochester Medical Center, Rochester, NY, United States.

PO026 Bile acid signaling remodels the iCCA immune microenvironment. Mirian Fernández-Vaquero. German Cancer Research Center, Heidelberg, Germany.

PO028, PR05 A novel kinase inhibitor for B-catenin mutant hepatocellular carcinoma. Alexander Rialdi. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PO031 Cannabidiol inhibits cell viability and induces apoptosis in hepatocellular carcinoma cell lines: The interplay between apoptosis and autophagy. Islam Yahiya. Faculty of Science, Alexandria University, Alexandria, Egypt.

PO032 Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-TRAIL-R Mediates Cholangiocarcinoma Tumor Immune Evasion by Enhancing Myeloid-Derived Suppressive Cell Population. Emilien Loeuillard. Mayo Clinic, Rochester, MN, United States.

PO033 A phase 1b/2 trial of PXS-5505 combined with first line atezolizumab plus bevacizumab for treating patients with unresectable or metastatic hepatocellular carcinoma. Paul R. Burchard. University of Rochester Medical Center, Rochester, NY, United States.